Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions

References

• Mukasa A, Ueki K, Matsumoto S et al. Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene 21(25), 3961–3968 (2002).
   Google Scholar
• Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79(7), 1381–1393 (1997).
   PubMed Web of Science ®Google Scholar
• Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera C, Chodkiewicz JP. Oligodendrogliomas. Part I: patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J. Neurooncol. 34(1), 37–59 (1997).
   Google Scholar
• Giannini C, Scheithauer BW, Weaver AL et al. Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J. Neuropathol. Exp. Neurol. 60(3), 248–262 (2001).
   PubMedGoogle Scholar
• Shaw E, Arusell R, Scheithauer B et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Co-operative Oncology Group study. J. Clin. Oncol. 20(9), 2267–2276 (2002).
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J. Clin. Oncol. 22(15), 3133–3138 (2004).
   PubMed Web of Science ®Google Scholar
• Mandonnet E, Delattre JY, Tanguy ML et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann. Neurol. 53(4), 524–528 (2003).
   PubMed Web of Science ®Google Scholar
• Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J. Neurosurg. 95(5), 735–745 (2001).
   PubMed Web of Science ®Google Scholar
• Karim AB, Afra D, Cornu P et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4, an interim analysis. Int. J. Radiat. Oncol. Biol. Phys. 52(2), 316–324 (2002).
   PubMed Web of Science ®Google Scholar
• Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54(7), 1442–1448 (2000).
   PubMed Web of Science ®Google Scholar
• Karim AB, Maat B, Hatlevoll R et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int. J. Radiat. Oncol. Biol. Phys. 36(3), 549–556 (1996).
   PubMed Web of Science ®Google Scholar
• Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 361(9354), 323–331 (2003).
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann. Neurol. 23(4), 360–364 (1988).
   PubMed Web of Science ®Google Scholar
• Glass J, Hochberg FH, Gruber ML, Louis DN, Smith D, Rattner B. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J. Neurosurg. 76(5), 741–745 (1992).
   PubMed Web of Science ®Google Scholar
• Cairncross G, Macdonald D, Ludwin S et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 12(10), 2013–2021 (1994).
   PubMed Web of Science ®Google Scholar
• Kim L, Hochberg FH, Thornton AF et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J. Neurosurg. 85(4), 602–607 (1996).
   PubMed Web of Science ®Google Scholar
• Buckner JC, Gesme D Jr, O’Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J. Clin. Oncol. 21(2), 251–255 (2003).
   PubMed Web of Science ®Google Scholar
• Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology 46(1), 203–207 (1996).
   PubMed Web of Science ®Google Scholar
• Pace A, Vidiri A, Galie E et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann. Oncol. 14(12), 1722–1726 (2003).
   PubMed Web of Science ®Google Scholar
• Brada M, Viviers L, Abson C et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann. Oncol. 14(12), 1715–1721 (2003).
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst. 90(19), 1473–1479 (1998).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 51(4), 1140–1145 (1998).
   PubMed Web of Science ®Google Scholar
• Paleologos NA, Macdonald DR, Vick NA, Cairncross JG. Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology 53(5), 1141–1143 (1999).
   PubMed Web of Science ®Google Scholar
• Quinn JA, Reardon DA, Friedman AH et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J. Clin. Oncol. 21(4), 646–651 (2003).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Taphoorn MJ, Brandes AA et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group study 26971. J. Clin. Oncol. 21(13), 2525–2528 (2003).
   PubMed Web of Science ®Google Scholar
• Chinot OL, Honore S, Dufour H et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J. Clin. Oncol. 19(9) 2449–2455 (2001).
   PubMed Web of Science ®Google Scholar
• Smith JS, Perry A, Borell TJ et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol.. 18(3) 636–645 (2000).
   PubMed Web of Science ®Google Scholar
• Kang SG, Kim JH, Nam do H et al. Clinical and radiological prognostic factors of anaplastic oligodendroglioma treated by combined therapy. Neurol. Med. Chir. (Tokyo) 45(5), 232–238; discussion 238–239 (2005).
   PubMed Web of Science ®Google Scholar
• Feigenberg SJ, Amdur RJ, Morris CG, Mendenhall WM, Marcus RB Jr, Friedman WA. Oligodendroglioma: does deferring treatment compromise outcome? Am J. Clin. Oncol. 26(3), E60–E66 (2003).
   Google Scholar
• Schiffer D, Dutto A, Cavalla P et al. Prognostic factors in oligodendroglioma. Can. J. Neurol. Sci. 24(4), 313–319 (1997).
   Google Scholar
• Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74(6), 1784–1791 (1994).
   PubMed Web of Science ®Google Scholar
• Mason W, Louis DN, Cairncross JG. Chemosensitive gliomas in adults: which ones and why? J. Clin. Oncol. 15(12), 3423–3426 (1997).
   Google Scholar
• Ino Y, Zlatescu MC, Sasaki H et al. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J. Neurosurg. 92(6), 983–990 (2000).
   PubMedGoogle Scholar
• Smith JS, Alderete B, Minn Y et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18(28), 4144–4152 (1999).
   PubMed Web of Science ®Google Scholar
• Cowell JK, Barnett GH, Nowak NJ. Characterization of the 1p/19q chromosomal loss in oligodendrogliomas using comparative genomic hybridization arrays (CGHa). J. Neuropathol. Exp. Neurol. 63(2), 151–158 (2004).
   Google Scholar
• Hashimoto N, Murakami M, Takahashi Y, Fujimoto M, Inazawa J, Mineura K. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p. Cancer 97(9), 2254–2261 (2003).
   PubMedGoogle Scholar
• Ino Y, Betensky RA, Zlatescu MC et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin. Cancer Res. 7(4), 839–845 (2001).
   PubMed Web of Science ®Google Scholar
• Bigner SH, Matthews MR, Rasheed BK et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am. J. Pathol. 155(2), 375–386 (1999).
   PubMed Web of Science ®Google Scholar
• Nigro JM, Takahashi MA, Ginzinger DG et al. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am. J. Pathol. 158(4), 1253–1262 (2001).
   Google Scholar
• Kraus JA, Koopmann J, Kaskel P et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J. Neuropathol. Exp. Neurol. 54(1), 91–95 (1995).
   PubMed Web of Science ®Google Scholar
• Louis DN, Gusella JF. A tiger behind many doors: multiple genetic pathways to malignant glioma. Trends Genet. 11(10), 412–415 (1995).
   PubMed Web of Science ®Google Scholar
• Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin. Cancer Res. 11(3), 1119–1128 (2005).
   PubMed Web of Science ®Google Scholar
• Kitange G, Misra A, Law M et al. Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. Genes Chromosomes Cancer 42(1), 68–77 (2005).
   Google Scholar
• Reifenberger G, Louis DN. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J. Neuropathol. Exp. Neurol. 62(2), 111–126 (2003).
   PubMed Web of Science ®Google Scholar
• Husemann K, Wolter M, Buschges R, Bostrom J, Sabel M, Reifenberger G. Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. J. Neuropathol. Exp. Neurol. 58(10), 1041–1050 (1999).
   Google Scholar
• Nutt CL, Noble M, Chambers AF, Cairncross JG. Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy. Cancer Res. 60(17), 4812–4818 (2000).
   PubMed Web of Science ®Google Scholar
• Tanaka S, Kamitani H, Amin MR et al. Preliminary individual adjuvant therapy for gliomas based on the results of molecular biological analyses for drug resistance genes. J. Neurooncol. 46(2), 157–171 (2000).
   PubMed Web of Science ®Google Scholar
• Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343(19), 1350–1354 (2000).
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Godard S et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res. 10(6), 1871–1874 (2004).
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Maintz D, Fiedler K, Koopmann J et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J. Neuropathol. Exp. Neurol. 56(10), 1098–1104 (1997).
   PubMed Web of Science ®Google Scholar
• Bello MJ, Leone PE, Nebreda P et al. Allelic status of chromosome 1 in neoplasms of the nervous system. Cancer Genet. Cytogenet. 83(2), 160–164 (1995).
   PubMedGoogle Scholar
• Shai R, Shi T, Kremen TJ et al. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22(31), 4918–4923 (2003).
   PubMed Web of Science ®Google Scholar
• Mischel PS, Shai R, Shi T et al. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 22(15), 2361–2323 (2003).
   PubMed Web of Science ®Google Scholar